By 2025, innovations such as lab-on-a-chip technology, automation, and CRISPR-Cas9 gene editing are expected to enhance ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Bengaluru-based biotechnology startup, CrisprBits Private Limited, has inaugurated a CRISPR gene editing and diagnostics ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Trusted by leading innovators worldwide, ERS Genomics is committed to providing responsible and effective access to CRISPR/Cas9 technology. To support small and early-stage organizations ...

CRISPR Therapeutics is a mid-stage biotech ... Investor enthusiasm about technology and growth stocks, and the economic environment ahead, drove the momentum. After all, the artificial ...

In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...